Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908829 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
A Phase 3 study, sponsored by Astellas Pharma Europe.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,174
- Enrollment target
NCT01908829 is a Phase 3 study that has completed, run by Astellas Pharma Europe. The registered enrollment target is 2,174 participants.
The verdict
NCT01908829, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,174 participants
- Enrollment target
Study Summary
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
Interventions
- DRUG mirabegron 25 mg
- DRUG mirabegron 50 mg
- DRUG solifenacin 5 mg
- DRUG solifenacin 10 mg
- DRUG mirabegron 25 mg matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,174 participants |
| Start Date | 2013-07-10 |
| Est. Completion | 2014-11-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908829
The ClinicalTrials.gov registry entry for NCT01908829 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mirabegron 25 mg is the first listed.
NCT01908829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908829 about?
NCT01908829 is a clinical study titled "A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)". The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
What is the current status of trial NCT01908829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,174 participants. The study started on 2013-07-10. Estimated completion is 2014-11-25.
What interventions are being tested in trial NCT01908829?
The interventions under investigation include: mirabegron 25 mg (DRUG), mirabegron 50 mg (DRUG), solifenacin 5 mg (DRUG), solifenacin 10 mg (DRUG), mirabegron 25 mg matching placebo (DRUG).
Who is sponsoring clinical trial NCT01908829?
This trial is sponsored by Astellas Pharma Europe, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.